PMID- 9544974
OWN - NLM
STAT- MEDLINE
DCOM- 19980421
LR  - 20190822
IS  - 0361-8609 (Print)
IS  - 0361-8609 (Linking)
VI  - 57
IP  - 4
DP  - 1998 Apr
TI  - Recombinant human granulocyte colony-stimulating factor (G-CSF) combined 
      conditioning regimen for allogeneic bone marrow transplantation (BMT) in 
      standard-risk myeloid leukemia.
PG  - 303-8
AB  - We previously suggested that using a combined conditioning regimen including 
      rhG-CSF with allogeneic BMT in refractory AML and CML in blast crisis might 
      reduce the rate of relapse and improve disease-free survival, without any major 
      side effects. In this study, we used the same protocol for 10 AML patients in 
      complete remission (CR) and 6 CML patients in the chronic phase (CP). We compared 
      disease-free survival as well as toxic side effects of the regimen with 6 AML 
      patients in CR and 6 CML patients in CP treated with chemoradiotherapy without 
      G-CSF. The conditioning regimen consisted of TBI and high-dose AraC. RhG-CSF was 
      infused continuously at a dose of 5 microg/kg/day, starting 24 hr before the 
      initial dose of total body irradiation (TBI) until the end of AraC therapy. In 
      all 28 cases, there were no early stage deaths due to regimen-related toxicity 
      (RRT). None of the 10 AML cases treated with the G-CSF combined regime relapsed. 
      In 6 AML cases treated conventionally without G-CSF, one patient died of 
      infection and another relapsed. There were no relapses in either CML group. In 
      the combined G-CSF group, one patient died of interstitial pneumonitis 48 days 
      after BMT, while the rest of the CML cases are still alive. There were no 
      relapses with rhG-CSF and no serious adverse effects in terms of RRT, acute graft 
      vs. host disease (GVHD), or leukocyte recovery.
FAU - Takahashi, S
AU  - Takahashi S
AD  - Department of Hematology/Oncology, The Institute of Medical Science, The 
      University of Tokyo, Japan.
FAU - Oshima, Y
AU  - Oshima Y
FAU - Okamoto, S
AU  - Okamoto S
FAU - Nishiwaki, K
AU  - Nishiwaki K
FAU - Nagayama, H
AU  - Nagayama H
FAU - Inoue, T
AU  - Inoue T
FAU - Tojo, A
AU  - Tojo A
FAU - Tani, K
AU  - Tani K
FAU - Asano, S
AU  - Asano S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (Recombinant Proteins)
RN  - 04079A1RDZ (Cytarabine)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Adult
MH  - Bone Marrow Transplantation/*methods
MH  - Cytarabine/adverse effects/therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Graft vs Host Reaction
MH  - Granulocyte Colony-Stimulating Factor/adverse effects/*therapeutic use
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
MH  - Leukemia, Myeloid/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm, Residual/complications
MH  - Recombinant Proteins
EDAT- 1998/04/17 02:03
MHDA- 2000/06/20 09:00
CRDT- 1998/04/17 02:03
PHST- 1998/04/17 02:03 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1998/04/17 02:03 [entrez]
AID - 10.1002/(SICI)1096-8652(199804)57:4<303::AID-AJH6>3.0.CO;2-Y [pii]
AID - 10.1002/(sici)1096-8652(199804)57:4<303::aid-ajh6>3.0.co;2-y [doi]
PST - ppublish
SO  - Am J Hematol. 1998 Apr;57(4):303-8. doi: 
      10.1002/(sici)1096-8652(199804)57:4<303::aid-ajh6>3.0.co;2-y.